Schrodinger/$SDGR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Schrodinger
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
Ticker
$SDGR
Sector
Primary listing
Industry
Health Care Technology
Headquarters
Employees
891
ISIN
US80810D1037
Website
Schrodinger Metrics
BasicAdvanced
$1.6B
-
-$2.64
1.84
-
Price and volume
Market cap
$1.6B
Beta
1.84
52-week high
$28.47
52-week low
$16.60
Average daily volume
1.2M
Financial strength
Current ratio
3.45
Quick ratio
3.303
Long term debt to equity
26.627
Total debt to equity
31.146
Profitability
EBITDA (TTM)
-186.44
Gross margin (TTM)
62.61%
Net profit margin (TTM)
-83.39%
Operating margin (TTM)
-83.63%
Effective tax rate (TTM)
-0.51%
Revenue per employee (TTM)
$260,000
Management effectiveness
Return on assets (TTM)
-16.27%
Return on equity (TTM)
-43.33%
Valuation
Price to revenue (TTM)
6.844
Price to book
4.25
Price to tangible book (TTM)
4.31
Price to free cash flow (TTM)
71.189
Free cash flow yield (TTM)
1.40%
Free cash flow per share (TTM)
30.41%
Growth
Revenue change (TTM)
22.29%
Earnings per share change (TTM)
32.40%
3-year revenue growth (CAGR)
14.27%
3-year earnings per share growth (CAGR)
11.50%
What the Analysts think about Schrodinger
Analyst ratings (Buy, Hold, Sell) for Schrodinger stock.
Bulls say / Bears say
Schrödinger reported a 63% year-over-year increase in total revenue for Q1 2025, reaching $59.6 million, indicating strong growth in both software and drug discovery segments. (businesswire.com)
The company received Fast Track Designation from the FDA for its MALT1 inhibitor, SGR-1505, for the treatment of relapsed/refractory Waldenström Macroglobulinemia, potentially accelerating its development and approval process. (businesswire.com)
Schrödinger secured a $150 million deal with Novartis, enhancing its financial position and validating its computational platform's value in drug discovery. (businesswire.com)
Despite revenue growth, Schrödinger reported a net loss of $59.8 million in Q1 2025, reflecting ongoing challenges in achieving profitability. (businesswire.com)
The company's software gross margin declined to 72% in Q1 2025 from 76% in the same quarter the previous year, indicating potential pricing pressures or increased costs. (businesswire.com)
Schrödinger's stock has experienced significant volatility, with a 52-week high of $28.47 and a low of $16.60, suggesting market uncertainty about its future performance. (marketingsentinel.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
Schrodinger Financial Performance
Revenues and expenses
Schrodinger Earnings Performance
Company profitability
Schrodinger News
AllArticlesVideos
Material Informatics Company Evaluation Report 2025 | Schrodinger, Dassault Systèmes, and Citrine Informatics Drive Market Growth Through AI, Simulation, and Collaboration
GlobeNewsWire·3 hours ago
Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia
Business Wire·3 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Schrodinger stock?
Schrodinger (SDGR) has a market cap of $1.6B as of July 18, 2025.
What is the P/E ratio for Schrodinger stock?
The price to earnings (P/E) ratio for Schrodinger (SDGR) stock is 0 as of July 18, 2025.
Does Schrodinger stock pay dividends?
No, Schrodinger (SDGR) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next Schrodinger dividend payment date?
Schrodinger (SDGR) stock does not pay dividends to its shareholders.
What is the beta indicator for Schrodinger?
Schrodinger (SDGR) has a beta rating of 1.84. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.